Literature DB >> 33913031

Ten-eleven translocase: key regulator of the methylation landscape in cancer.

Jyoti Shekhawat1, Kavya Gauba1, Shruti Gupta1, Bikram Choudhury2, Purvi Purohit1, Praveen Sharma1, Mithu Banerjee3.   

Abstract

PURPOSE: Methylation of 5th residue of cytosine in CpG island forms 5-methylcytosine which is stable, heritable epigenetic mark. Methylation levels are broadly governed by methyltransferases and demethylases. An aberration in the demethylation process contributes to the silencing of gene expression. Ten eleven translocation (TET) dioxygenase (1-3) the de novo demethylase is responsible for conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosisne (5-fC) and 5-carboxycytosine (5-caC) during demethylation process. Mutations and abnormal expression of TET proteins contribute to carcinogenesis. Discovery of TET proteins has offered various pathways for the reversal of methylation levels thus, enhancing our knowledge as to how methylation effects cancer progression.
METHODS: We searched "PubMed" and "Google scholar" databases and selected studies with the following keywords "TET enzyme", "cancer", "5-hmC", and "DNA demethylation". In this review, we have discussed combinatorial use of vitamin C in inhibiting tumour growth by enhancing the catalytic activity of TET enzymes and consequently, increasing the 5-hmC levels. 5-Hydroxymethylcytosine holds promise as a prognostic biomarker in solid cancers. The contribution of induction and suppression of TET enzymes and 5-hmC carcinogenesis are discussed in haematological and solid cancers.
RESULTS: We found that TET enzymes play central role in maintaining the methylation balance. Any anomaly in their expression may dip the balance towards cancer progression. Low levels of TET enzymes and 5-hmC correlate with tumour invasion, progression and metastasis. Also, use of vitamin C enhances TET activity.
CONCLUSION: TET enzymes play vital role in shaping the methylation landscape in body. 5-hmC can be used as prognostic marker in solid cancers.

Entities:  

Keywords:  5-Hydroxymethylcytosine; 5-Methylcytosine; Cancer; DNA demethylation; Epigenetics; TET enzymes

Year:  2021        PMID: 33913031     DOI: 10.1007/s00432-021-03641-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  85 in total

Review 1.  DNA methylation and the preservation of cell identity.

Authors:  Ozren Bogdanović; Ryan Lister
Journal:  Curr Opin Genet Dev       Date:  2017-06-24       Impact factor: 5.578

2.  Transcript levels of ten-eleven translocation type 1-3 in cervical cancer and non-cancerous cervical tissues.

Authors:  Dorota Ewa Bronowicka-Kłys; Andrzej Roszak; Piotr Pawlik; Stefan Sajdak; Anna Sowińska; Paweł Piotr Jagodziński
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

Review 3.  Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.

Authors:  Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Alexander Kohlmann; Wolfgang Kern; Torsten Haferlach
Journal:  Ann Hematol       Date:  2010-03-02       Impact factor: 3.673

4.  The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.

Authors:  Thomas Burmeister; Claus Meyer; Stefan Schwartz; Julia Hofmann; Mara Molkentin; Eric Kowarz; Björn Schneider; Thorsten Raff; Richard Reinhardt; Nicola Gökbuget; Dieter Hoelzer; Eckhard Thiel; Rolf Marschalek
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

5.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

Review 6.  Mammalian X-chromosome inactivation and the XIST gene.

Authors:  A Ballabio; H F Willard
Journal:  Curr Opin Genet Dev       Date:  1992-06       Impact factor: 5.578

7.  MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis.

Authors:  Qing Chen; Dan Yin; Yong Zhang; Lei Yu; Xue-Dong Li; Zheng-Jun Zhou; Shao-Lai Zhou; Dong-Mei Gao; Jie Hu; Cheng Jin; Zheng Wang; Ying-Hong Shi; Ya Cao; Jia Fan; Zhi Dai; Jian Zhou
Journal:  Cell Death Dis       Date:  2017-06-29       Impact factor: 8.469

8.  α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis.

Authors:  Sandra Atlante; Alessia Visintin; Elisabetta Marini; Matteo Savoia; Chiara Dianzani; Marta Giorgis; Duran Sürün; Federica Maione; Frank Schnütgen; Antonella Farsetti; Andreas M Zeiher; Massimo Bertinaria; Enrico Giraudo; Francesco Spallotta; Chiara Cencioni; Carlo Gaetano
Journal:  Cell Death Dis       Date:  2018-07-09       Impact factor: 8.469

Review 9.  Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis.

Authors:  Tiefeng Cao; Wenwei Pan; Xiaoli Sun; Huimin Shen
Journal:  J Ovarian Res       Date:  2019-10-27       Impact factor: 4.234

View more
  3 in total

Review 1.  Mechanisms that regulate the activities of TET proteins.

Authors:  Kanak Joshi; Shanhui Liu; Peter Breslin S J; Jiwang Zhang
Journal:  Cell Mol Life Sci       Date:  2022-06-15       Impact factor: 9.207

Review 2.  Vitamin C Intake and Cancers: An Umbrella Review.

Authors:  Zeyu Chen; Yin Huang; Dehong Cao; Shi Qiu; Bo Chen; Jin Li; Yige Bao; Qiang Wei; Ping Han; Liangren Liu
Journal:  Front Nutr       Date:  2022-01-20

3.  MiR-27a-3p binds to TET1 mediated DNA demethylation of ADCY6 regulates breast cancer progression via epithelial-mesenchymal transition.

Authors:  Hao Wu; Juanjuan Qiu; Zhenru Wu; Tao He; Chen Zhou; Qing Lv
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.